Skip to content

The Biggest 2014 Growth Driver Orphan Drugs

August 20, 2014

.

.

FirstWord Pharma, a supplier of global news and intelligence to the pharmaceutical industry, publishes a list of the top 25 biggest growth driver drugs for the first half (H1) of 2014 versus H1 of 2013. The Chart below identifies the orphan drugs from the list of the top 25.

Biggest Growth Driver Orphan Drugs (H1 2014 vs. H1 2013)

FirstWord Pharma Ranking Product Sponsor Company Growth

($ Millions)

3 Humira AbbieVie $1075
8 Soliris Alexion Pharmaceuticals $371
11 Revlimid Celgene $303
13 Remicade Johnson & Johnson/ Merck $277
21 Pomalyst Celgene $202
22 Avastin Roche $173
24 Herceptin Roche $168

Source of Data: Company Reported Data (FirstWorld Pharma article)

OBSERVATIONS

•    AbbieVie’s orphan drug Humira increases in sales of approximately $1 billion for the 1st half of 2014 versus the 1st half of 2013

•    Celgene’s recent launch of Pomalyst is identified as a “key growth driver” by FirstWord Pharma; Celgene also has a strong oncology presence in this list

•    Roche’s cancer franchise, including orphan drugs Avastin and Herceptin, shows the “commercial longevity for biologic therapies”

•    Oncology and inflammatory indications dominate the orphan drug list.

Please Note: “Interferon” courtesy of Linda Bartlett (Photographer) from the National Cancer Institute (NCI). [Public domain in the US].

Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: